Leerink Partnrs Issues Optimistic Forecast for VRDN Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities researchers at Leerink Partnrs lifted their FY2025 earnings estimates for Viridian Therapeutics in a research note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.88) per share for the year, up from their previous forecast of ($4.21). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics’ Q4 2025 earnings at ($0.77) EPS, FY2026 earnings at ($2.33) EPS and FY2027 earnings at ($1.69) EPS.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.48. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The firm’s revenue was up 81993.0% compared to the same quarter last year.

Several other research analysts have also issued reports on the company. Needham & Company LLC reduced their price target on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Wells Fargo & Company decreased their price objective on Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, October 8th. BTIG Research restated a “buy” rating and set a $61.00 target price on shares of Viridian Therapeutics in a report on Tuesday, November 4th. Finally, Royal Bank Of Canada increased their price target on Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $39.78.

Viridian Therapeutics Trading Up 2.8%

Shares of VRDN opened at $28.43 on Monday. The stock’s fifty day simple moving average is $21.68 and its 200-day simple moving average is $17.77. The firm has a market capitalization of $2.71 billion, a PE ratio of -7.42 and a beta of 0.72. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $28.86. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04.

Insider Transactions at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc acquired 454,545 shares of the firm’s stock in a transaction dated Thursday, October 23rd. The stock was bought at an average cost of $22.00 per share, for a total transaction of $9,999,990.00. Following the completion of the transaction, the director directly owned 3,914,458 shares in the company, valued at $86,118,076. This represents a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.58% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Viridian Therapeutics by 1.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after purchasing an additional 876 shares during the period. Knights of Columbus Asset Advisors LLC raised its position in Viridian Therapeutics by 2.4% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company’s stock valued at $1,282,000 after buying an additional 1,386 shares during the last quarter. Swiss National Bank lifted its position in shares of Viridian Therapeutics by 1.3% during the second quarter. Swiss National Bank now owns 108,900 shares of the company’s stock valued at $1,522,000 after purchasing an additional 1,400 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Viridian Therapeutics by 332.1% during the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after purchasing an additional 1,491 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Viridian Therapeutics by 0.8% in the 1st quarter. Bank of New York Mellon Corp now owns 198,177 shares of the company’s stock worth $2,671,000 after purchasing an additional 1,655 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.